# Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

> **NCT04281485** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 114 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **GENETIC:** PF-06939926
- **OTHER:** Placebo
- **OTHER:** Placebo
- **GENETIC:** PF-06939926

## Key facts

- **NCT ID:** NCT04281485
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-05
- **Primary completion:** 2024-05-15
- **Final completion:** 2039-04-15
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04281485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04281485, "Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04281485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*